Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.

Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint c...

Full description

Bibliographic Details
Main Authors: Sam Debaveye, Delphine De Smedt, Bert Heirman, Shane Kavanagh, Jo Dewulf
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0229235
id doaj-8829969f2fe4404ba8bae3b53c3216a4
record_format Article
spelling doaj-8829969f2fe4404ba8bae3b53c3216a42021-03-03T21:31:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01152e022923510.1371/journal.pone.0229235Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.Sam DebaveyeDelphine De SmedtBert HeirmanShane KavanaghJo DewulfLife Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint concerning one AoP: Human Health. We propose to take this one step further by simultaneously comparing the quantified handprint and footprint on all AoPs through normalization and weighting of the results towards a single score. We discuss two example cases of a pharmaceutical treatment: mebendazole to treat soil-transmitted helminthiases and paliperidone palmitate to treat schizophrenia. Each time, treatment is compared to 'no treatment'. The footprint of health care is compared to the handprint of improved patient health. The handprint and footprint were normalized separately. To include sensitivity in the normalization step we applied four sets of external normalization factors for both handprint (Global Burden of Disease) and footprint (ReCiPe and PROSUITE). At the weighting step we applied 26 sets of panel weighting factors from three sources. We propose the Relative Sustainability Benefit Rate (RSBR) as a new metric to quantify the relative difference in combined handprint and footprint single score between two alternatives. When only considering the footprint, the first case study is associated with an increased single score burden of treatment compared to 'no treatment', while in the second case study treatment reduces the single score burden by 41.1% compared to 'no treatment'. Also including the handprint provided new insights for the first case study, now showing a decrease of 56.4% in single score burden for treatment compared to 'no treatment'. For the second case study the reduction of single score burden was confirmed as the handprint burden was also decreased because of treatment by 9.9%, reinforcing the findings.https://doi.org/10.1371/journal.pone.0229235
collection DOAJ
language English
format Article
sources DOAJ
author Sam Debaveye
Delphine De Smedt
Bert Heirman
Shane Kavanagh
Jo Dewulf
spellingShingle Sam Debaveye
Delphine De Smedt
Bert Heirman
Shane Kavanagh
Jo Dewulf
Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
PLoS ONE
author_facet Sam Debaveye
Delphine De Smedt
Bert Heirman
Shane Kavanagh
Jo Dewulf
author_sort Sam Debaveye
title Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
title_short Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
title_full Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
title_fullStr Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
title_full_unstemmed Quantifying the handprint-Footprint balance into a single score: The example of pharmaceuticals.
title_sort quantifying the handprint-footprint balance into a single score: the example of pharmaceuticals.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2020-01-01
description Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint concerning one AoP: Human Health. We propose to take this one step further by simultaneously comparing the quantified handprint and footprint on all AoPs through normalization and weighting of the results towards a single score. We discuss two example cases of a pharmaceutical treatment: mebendazole to treat soil-transmitted helminthiases and paliperidone palmitate to treat schizophrenia. Each time, treatment is compared to 'no treatment'. The footprint of health care is compared to the handprint of improved patient health. The handprint and footprint were normalized separately. To include sensitivity in the normalization step we applied four sets of external normalization factors for both handprint (Global Burden of Disease) and footprint (ReCiPe and PROSUITE). At the weighting step we applied 26 sets of panel weighting factors from three sources. We propose the Relative Sustainability Benefit Rate (RSBR) as a new metric to quantify the relative difference in combined handprint and footprint single score between two alternatives. When only considering the footprint, the first case study is associated with an increased single score burden of treatment compared to 'no treatment', while in the second case study treatment reduces the single score burden by 41.1% compared to 'no treatment'. Also including the handprint provided new insights for the first case study, now showing a decrease of 56.4% in single score burden for treatment compared to 'no treatment'. For the second case study the reduction of single score burden was confirmed as the handprint burden was also decreased because of treatment by 9.9%, reinforcing the findings.
url https://doi.org/10.1371/journal.pone.0229235
work_keys_str_mv AT samdebaveye quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT delphinedesmedt quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT bertheirman quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT shanekavanagh quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT jodewulf quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
_version_ 1714816504745164800